Evidence mapPaperPMID 37712012Full record

ReviewSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2023

A narrative review of approved and emerging anti-obesity medications.

Semira Abdi Beshir, Asim Ahmed Elnour, Aadith Soorya, Affana Parveen Mohamed, Sheron Sir Loon Goh, Nadia Hussain, Amal H I Al Haddad, Faizah Hussain, Israa Yousif Khidir, Zainab Abdelnassir

Erratum issuedOpen access · hybridAbstract readReview
In one paragraph

Review in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
11.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Palmitoylethanolamide in Human and Animal Obesity.Molecules (Basel, Switzerland) · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Systemic inhibition ofbioRxiv : the preprint server for biology · 2024
    Article
  16. Article
  17. Review
  18. Association betweenGenes · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Semira Abdi BeshirDepartment of clinical pharmacy and Pharmacotherapeutics, Dubai Pharmacy College For Girls, Dubai, United Arab Emirates.
Asim Ahmed ElnourProgram of Clinical Pharmacy, College of Pharmacy, Al Ain University, Abu Dhabi Campus, United Arab Emirates.
Aadith SooryaCollege of Medicine, Gulf Medical University, Ajman, United Arab Emirates.
Affana Parveen MohamedCollege of Pharmacy, Gulf Medical University, Ajman, United Arab Emirates.
Sheron Sir Loon GohDepartment of Primary Care Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Nadia HussainDepartment of Pharmaceutical Sciences, College of Pharmacy, 105949, Al Ain University, Al Ain, United Arab Emirates.
Amal H I Al HaddadChief Operation Officer, Sheikh Shakhbout Medical City (SSMC), Abu Dhabi, United Arab Emirates.
Faizah HussainDepartment of clinical pharmacy and Therapeutics, Dubai Pharmacy College, Dubai, United Arab Emirates.
Israa Yousif KhidirDepartment of Clinical Pharmacy and Pharmacy Practice, (PhD, MSc, B Pharm), College of Pharmacy, University of Hail (UOH), Saudi Arabia.
Zainab AbdelnassirFourth-year pharmacy, Abu Dhabi, United Arab Emirates.
Al Ain University · AEDubai Pharmacy College · AEGulf Medical University · AESheikh Shakhbout Medical City · AEUniversity of Ha'il · SAUniversity of Malaya · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Recently, many drugs have been approved for halting overweight and obesity-few types of research shifted to using Anti-obesity medications (AOM) solely for well-being and shape-keeping. Objective: This narrative review's objective was to explore the use of AOM in relation to their medical indications, efficacy, and cardiovascular safety. Methods and materials: We have conducted a narrative review of the literature on approved/non-approved AOM used for obesity and overweight. We have shed light on the emerging trials of therapies and evolving remedies. Results: Recently, there has been an enormous change in the use of AOM with high consumption that deserves extensive surveillance for the long-term consequences and impact on social, mental, and physical health. Nearly six AOMs and combined therapy are approved by the Food and Drug Administration. The recent guidelines for obesity management have shifted the focus from weight loss to goals that the patient considers essential and toward targeting the root cause of obesity. Conclusion: The use of AOM increased enormously despite its sometimes-dubious safety and ineffectiveness. The public and medical professionals should be vigilant to the real-world benefits of anti-obesity drugs and their achieved effectiveness with an improved safety profile.

Indexed as

Anti-obesity medications (AOM)Liraglutide (Saxenda)Naltrexone-bupropion (Contrave)ObesityOrlistat (Xenical)OverweightPhentermine (Ponderax)Phentermine-topiramate (Qsymia)Semaglutide (Wegovy)Setmelanotide (IMCIVREE)Tirzepatide (Mounjaro)Type 2 diabetes mellitus (T2DM)

Identifiers

PMID37712012
PMCPMC10497995
OpenAlexW4386122686

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.